Ann: IMU Meets Endpoints in Phase 1b Gastric Cancer Trial, page-106

we have to keep in mind that ,

1) very important - this is giving hopes to patients who are almost in 4h stage

2) This will be a low cost vaccine - target includes asia and other countries where population cannot afford a 500k vaccine to live

3) This is targeted to region where gastric cancer is very prevalent

4) This is in combination with chemo , but permutation and combination with other cancer immunotherapy is endless

I discussed this with my brother who is MCH in gastric , he seems to acknowledge that this is very exiting and its encouraging we got human trails in phase 1 and moving to phase 2 with this result is very positive , but yes phase 2 is where most fail but with this type of phase 1 results the success rate is very high ,but he also mentioned the report is bit light weight but also considering the fact that company was trying to put it out in lay mans language as possible to get the message out to investors who are mostly from non medical background